I have read the letter once and I couldn’t disagree with you more strongly. I suggest that the premise -
“BIT 225 uniquely combines direct antiviral activity with restoration of normal immune regulation through it’s targeting of viroporin activity “ is without any foundation whatsoever.
How can they possibly deduce that?.
Also -
“importantly, in the 010 trial blood virus levels decreased more quickly in people on BiT225+ART compared to ART alone. This suggests that BIT225 is having an on a critical phase of viral decay when reservoirs are established “. What!!!, how do you work that link out?, it mealy suggests it assists the ART drugs in eliminating the virus - has got no tangible link to reservoirs.
I feel Biotron is making unsubstantiated premises about BIT225 and the depletion of viral loads within reservoirs.
I have read the letter once and I couldn’t disagree with you...
-
- There are more pages in this discussion • 123 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.14M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 1.9¢ | 1.9¢ | $7.664K | 403.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 1.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.0¢ | 1202498 | 5 |
View Market Depth
| Last trade - 13.42pm 27/09/2024 (20 minute delay) ? |
| BIT (ASX) Chart |